Fluorenone Drug for Treatment of Combat-Related Traumatic Optic Neuropathy

Abstract

Traumatic optic neuropathy (TON) is a frequent cause of significant visual loss after combat-related frontal head trauma. There is no clinically proven therapy for improving visual outcomes in TON patients. Identification of new treatment options for TON is of highest priority. Our goal is to conduct studies needed to advance the proposed drug candidate, B-3(+), to clinical development for the TON indication. The following specific aims have been identified in order to attain the study objective: Develop a standard in vitro ADMET package required to support pre-clinical and clinical development of the drug candidate (Specific Aim 1); Conduct systemic and ocular pharmacokinetic studies in beagle dogs; use blood samples collected in PK studies for assessing drug nephrotoxicity (Specific Aim 2); Expand upon existing pre-clinical efficacy data and develop a robust efficacy package that can convincingly justify compound testing in patients with traumatic optic neuropathy (Specific Aim 3).

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2021
Accession Number
AD1155400

Entities

People

  • Konstantin Petrukhin

Organizations

  • Columbia University

Tags

DTIC Thesaurus Topics

  • Animals
  • Biomedical Research
  • Brain Injuries
  • Cells
  • Craniocerebral Trauma
  • Culture Techniques
  • Data Analysis
  • Fluorenones
  • Inhibitors
  • Maryland
  • Medical Personnel
  • Neuropathy
  • New York
  • Optic Nerve
  • Rodents
  • Standards
  • Universities

Fields of Study

  • Medicine
  • Psychology

Readers

  • Neurotrauma and Rehabilitation Medicine.
  • Oncology
  • Toxicology/Environmental Toxicology